Fig. 1 · Structure
Documents & Downloads
Sirtratumab vedotin
Anti-SLITRK6 ADC
Sirtratumab vedotin is an antibody-drug conjugate (ADC) targeting SLITRK6. This compound comprises a human gamma 2 antibody that specifically recognizes SLITRK6, conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) through a protease-cleavable linker. Sirtratumab vedotin demonstrates significant cytotoxic activity in SLITRK6-expressing tumor cells, making it a valuable tool for research on targeted cancer therapies and the development of personalized treatment strategies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1824663-83-3 |
| Applications | Anti-SLITRK6 ADC |
| Synonyms | AGS15E; ASG-15ME; 1vcMMAE |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.